المؤلفون: Pianko, S, Zeuzem, S, Chuang, WL, Foster, GR, Sarin, SK, Flisiak, R, Lee, CM, Andreone, P, Piratvisuth, T, Shah, S, Sood, A, George, J, Gould, M, Komolmit, P, Thongsawat, S, Tanwandee, T, Rasenack, J, Li, Y, Pang, M, Yin, Y, Feutren, G, Jacobson, IM, CRAXI, Antonio

المساهمون: Pianko, S, Zeuzem, S, Chuang, WL, Foster, GR, Sarin, SK, Flisiak, R, Lee, CM, Andreone, P, Piratvisuth, T, Shah, S, Sood, A, George, J, Gould, M, Komolmit, P, Thongsawat, S, Tanwandee, T, Rasenack, J, Li, Y, Pang, M, Yin, Y, Feutren, G, Jacobson, IM, Craxi, A

مصطلحات موضوعية: hepatitis C

العلاقة: info:eu-repo/semantics/altIdentifier/wos/WOS:000307165900004; volume:19; firstpage:623; lastpage:634; numberofpages:12; journal:JOURNAL OF VIRAL HEPATITIS; http://hdl.handle.net/10447/73840Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-84864665171

الإتاحة: http://hdl.handle.net/10447/73840Test

المؤلفون: Byrtus, A, Bastgen, D, Byrtus, J, Trebicka, J, Treitl, M, Sauerbruch, T, Schultheiss, M, Rasenack, J, Thimme, R, Jacobs, S, Grandt, D, Rössle, M

المصدر: 35. Jahrestagung der Deutschen Arbeitsgemeinschaft zum Studium der Leber ; Zeitschrift für Gastroenterologie ; ISSN 1439-7803

الإتاحة: https://doi.org/10.1055/s-0038-1677120Test

المؤلفون: Foster, G. R., Zeuzem, S., Pianko, S., Sarin, S. K., Piratvisuth, T., Shah, S., Andreone, P., Sood, A., Chuang, W.‐L., Lee, C.‐M., George, J., Gould, M., Flisiak, R., Jacobson, I. M., Komolmit, P., Thongsawat, S., Tanwandee, T., Rasenack, J., Sola, R., Messina, I., Yin, Y., Cammarata, S., Feutren, G., Brown, K. K.

المساهمون: Novartis, HGS

المصدر: Journal of Viral Hepatitis ; volume 20, issue 4 ; ISSN 1352-0504 1365-2893

الوصف: Summary Rare interstitial lung disease cases have been reported with albinterferon alfa‐2b (alb IFN ) and pegylated interferon alfa‐2a (Peg‐ IFN α‐2a) in chronic hepatitis C virus ( HCV ) patients. Systematic pulmonary function evaluation was conducted in a study of alb IFN q4wk vs Peg‐ IFN α‐2a qwk in patients with chronic HCV genotypes 2/3. Three hundred and ninety‐one patients were randomly assigned 4:4:4:3 to one of four, open‐label, 24‐week treatment groups including oral ribavirin 800 mg/d: alb IFN 900/1200/1500 μg q4wk or Peg‐ IFN α‐2a 180 μg qwk. Standardized spirometry and diffusing capacity of the lung for carbon monoxide ( DLCO ) were recorded at baseline, weeks 12 and 24, and 6 months posttreatment, and chest X‐rays ( CXR s) at baseline and week 24. Baseline spirometry and DLCO were abnormal in 35 (13%) and 98 (26%) patients, respectively. Baseline interstitial CXR findings were rare (4 [1%]). During the study, clinically relevant DLCO declines (≥15%) were observed in 173 patients (48%), and were more frequent with Peg‐ IFN α‐2a and alb IFN 1500 μg; 24 weeks posttreatment, 57 patients (18%) still had significantly decreased DLCO , with a pattern for greater rates with alb IFN vs Peg‐ IFN α‐2a. One patient developed new interstitial CXR abnormalities, but there were no clinically relevant interstitial lung disease cases. The risk of persistent posttreatment DLCO decrease was not related to smoking, alcohol, HCV genotype, sustained virologic response, or baseline viral load or spirometry. Clinically relevant DLCO declines occurred frequently in chronic HCV patients receiving IFN α/ribavirin therapy and commonly persisted for ≥6 months posttherapy. The underlying mechanism and clinical implications for long‐term pulmonary function impairment warrant further research.

الإتاحة: https://doi.org/10.1111/jvh.12020Test

المؤلفون: Wiegand, J., Neumann, K., Bohm, S., Weich, V., Teuber, G., Klinker, H., Moller, B., Rasenack, J., Hinrichsen, H., Gerlach, T., Spengler, U., Buggisch, P., Sarrazin, C., Berg, T.

المصدر: Clinical Infectious Diseases ; volume 53, issue 11, page 1111-1114 ; ISSN 1058-4838 1537-6591

مصطلحات موضوعية: Infectious Diseases, Microbiology (medical)

الإتاحة: https://doi.org/10.1093/cid/cir670Test
http://academic.oup.com/cid/article-pdf/53/11/1111/868545/cir670.pdfTest

المؤلفون: Buti, M., Flisiak, R., Rasenack, J., Davis, G., Alberti, A., Goeser, T., Stanciu, C., Chuang, W. -L., Kao, J. -H., Streinu-Cercel, A., Hofstetter, G., Wang, J., Avila, C., Orsenigo, R., Tabak, F.

المساهمون: Hospital Universitari Vall d''Hebron ,, 141453

مصطلحات موضوعية: Sağlık Bilimleri, Klinik Tıp, GASTROENTEROLOJİ VE HEPATOLOJİ, Klinik Tıp (MED), Tıp, Dahili Tıp Bilimleri, İç Hastalıkları, Gastroenteroloji-(Hepatoloji)

العلاقة: Buti M., Flisiak R., Rasenack J., Davis G., Alberti A., Goeser T., Stanciu C., Chuang W. -. , Tabak F., Kao J. -. , et al., "ALISPORIVIR (ALV) PLUS PEGINTERFERON/RIBAVIRIN (PR) ACHIEVES HIGH SVR12 RATES AMONG NULL RESPONDERS, IL28BCT/TT AND CIRRHOTIC HCVG1 PATIENTS (FUNDAMENTAL STUDY INTERIM ANALYSIS)", International Liver Congress / 48th Annual Meeting of the European-Association-for-the-Study-of-the-Liver (EASL), Amsterdam, Hollanda, 24 - 28 Nisan 2013, cilt.58; vv_1032021; av_60e7879e-7540-4d70-a6f7-cb86080698d3; http://hdl.handle.net/20.500.12627/67606Test; https://doi.org/10.1016/s0168-8278Test(13)61420-8; 58

الإتاحة: https://doi.org/20.500.12627/67606Test
https://doi.org/10.1016/s0168-8278Test(13)61420-8
https://hdl.handle.net/20.500.12627/67606Test

المؤلفون: Bzowej, N, Thongsawat, S, Wang, Y, Chen, Y, Heathcote, EJ, Rasenack, J, Naoumov, NV, Di Bisceglie, AM, Zeuzem, S, Moon, YM, Goodman, Z, Chao, G, Constance, BF, Brown, NA, Hsu, CW, Liaw, YF, Gane, E, Lai, CL

مصطلحات موضوعية: Nucleosides - adverse effects - therapeutic use, Pyrimidinones - adverse effects - therapeutic use, Hepatitis B, Chronic - drug therapy, Lamivudine - adverse effects - therapeutic use, Antiviral Agents - adverse effects - therapeutic use

الوصف: BACKGROUND: Reducing hepatitis B virus (HBV) replication to minimal levels is emerging as a key therapeutic goal for chronic hepatitis B. METHODS: In this double-blind, phase 3 trial, 1370 patients with chronic hepatitis B were randomly assigned to receive 600 mg of telbivudine or 100 mg of lamivudine once daily. The primary efficacy end point was noninferiority of telbivudine to lamivudine for therapeutic response (i.e., a reduction in serum HBV DNA levels to fewer than 5 log 10 copies per milliliter, along with loss of hepatitis B e antigen [HBeAg] or normalization of alanine aminotransferase levels). Secondary efficacy measures included histologic response, changes in serum HBV DNA levels, and HBeAg responses. RESULTS: At week 52, a significantly higher proportion of HBeAg-positive patients receiving telbivudine than of those receiving lamivudine had a therapeutic response (75.3% vs. 67.0%, P = 0.005) or a histologic response (64.7% vs. 56.3%, P = 0.01); telbivudine also was not inferior to lamivudine for these end points in HBeAg-negative patients. In HBeAg-positive and HBeAg-negative patients, telbivudine was superior to lamivudine with respect to the mean reduction in the number of copies of HBV DNA from baseline, the proportion of patients with a reduction in HBV DNA to levels undetectable by polymerase-chain-reaction assay, and development of resistance to the drug. Elevated creatine kinase levels were more common in patients who received telbivudine, whereas elevated alanine aminotransferase and aspartate aminotransferase levels were more common in those who received lamivudine. CONCLUSIONS: Among patients with HBeAg-positive chronic hepatitis B, the rates of therapeutic and histologic response at 1 year were significantly higher in patients treated with telbivudine than in patients treated with lamivudine. In both the HBeAg-negative and the HBeAg-positive groups, telbivudine demonstrated greater HBV DNA suppression with less resistance than did lamivudine. (ClinicalTrials.gov number, NCT00057265.) ...

العلاقة: New England Journal of Medicine; http://www.scopus.com/mlt/select.url?eid=2-s2.0-37349120537&selection=ref&src=s&origin=recordpageTest; New England Journal Of Medicine, 2007, v. 357 n. 25, p. 2576-2588; 2588; 1098824; 149250; WOS:000251728900008; 25; http://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0028-4793&volume=357&issue=25&spage=2576&epage=2588&date=2007&atitle=Telbivudine+versus+lamivudine+in+patients+with+chronic+hepatitis+BTest; eid_2-s2.0-37349120537; 2576; http://hdl.handle.net/10722/57525Test; 357

الإتاحة: https://doi.org/10.1056/NEJMoa066422Test
http://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0028-4793&volume=357&issue=25&spage=2576&epage=2588&date=2007&atitle=Telbivudine+versus+lamivudine+in+patients+with+chronic+hepatitis+BTest
http://hdl.handle.net/10722/57525Test

المؤلفون: Kamal, S M, El Tawil, A A, Nakano, T, He, Q, Rasenack, J, Hakam, S A, Saleh, W A, Ismail, A, Aziz, A A, Madwar, M Ali

مصطلحات موضوعية: Viral hepatitis

الوصف: Background: The response rates and duration of peginterferon alpha (PEG-IFN-α) and ribavirin combination therapy in chronic hepatitis C genotype 4, the prevalent genotype in the Middle East and Africa, are poorly documented. Aims: To compare the efficacy and safety of 24, 36, or 48 weeks of PEG-IFN-α-2b and ribavirin therapy in chronic hepatitis C genotype 4. Methods: In this prospective, randomised, double blind study, 287 patients with chronic hepatitis C genotype 4 were randomly assigned to PEG-IFN-α-2b (1.5 μg/kg) once weekly plus daily ribavirin (1000–1200 mg) for 24 weeks (group A, n = 95), 36 weeks (group B, n = 96), or 48 weeks (group C, n = 96) and followed for 48 weeks after completion of treatment. Early viral kinetics and histopathological evaluation of pre- and post treatment liver biopsies were performed. The primary end point was viral clearance 48 weeks after completion of treatment. Results: Sustained virological response was achieved in 29%, 66%, and 69% of patients treated with PEG-IFN-α-2b and ribavirin for 24, 36, and 48 weeks, respectively, by intention to treat analysis. No statistically significant difference in sustained virological response rates was detected between 36 and 48 weeks of therapy (p = 0.3). Subjects with sustained virological response showed greater antiviral efficacy (ε) and rapid viral load decline from baseline to treatment week 4 compared with non-responders and improvement in liver histology. The incidence of adverse events was higher in the group treated for 48 weeks. Conclusion: PEG-IFN-α-2b and ribavirin for 36 or 48 weeks was more effective in the treatment of chronic hepatitis C genotype 4 than treatment for 24 weeks. Thirty six week therapy was well tolerated and produced sustained virological and histological response rates similar to the 48 week regimen.

وصف الملف: text/html

العلاقة: http://gut.bmj.com/cgi/content/short/54/6/858Test; http://dx.doi.org/10.1136/gut.2004.057182Test

الإتاحة: https://doi.org/10.1136/gut.2004.057182Test
http://gut.bmj.com/cgi/content/short/54/6/858Test

المؤلفون: Kreisel, W, Potthoff, K, Bertz, H, Schmitt-Graeff, A, Ruf, G, Rasenack, J, Finke, J

المصدر: Bone Marrow Transplantation ; volume 32, issue 3, page 337-340 ; ISSN 0268-3369 1476-5365

مصطلحات موضوعية: Transplantation, Hematology

الإتاحة: https://doi.org/10.1038/sj.bmt.1704134Test
https://www.nature.com/articles/1704134Test
https://www.nature.com/articles/1704134.pdfTest

المؤلفون: Gross, V, Andus, T, Ecker, K W, Raedler, A, Loeschke, K, Plauth, M, Rasenack, J, Weber, A, Gierend, M, Ewe, K, Schölmerich, J, Budesonide Study Group

مصطلحات موضوعية: INFLAMMATION AND INFLAMMATORY BOWEL DISEASE

وصف الملف: text/html

العلاقة: http://gut.bmj.com/cgi/content/short/42/4/493Test; http://dx.doi.org/10.1136/gut.42.4.493Test

الإتاحة: https://doi.org/10.1136/gut.42.4.493Test
http://gut.bmj.com/cgi/content/short/42/4/493Test

المؤلفون: Grotz, W. H., Mundinger, F. A., Muller, C. B., Rasenack, J., Schulte-Monting, J., Langer, M. F., Schollmeyer, P. J.

المصدر: Nephrology Dialysis Transplantation ; volume 12, issue 3, page 564-569 ; ISSN 0931-0509 1460-2385

مصطلحات موضوعية: Transplantation, Nephrology

الإتاحة: https://doi.org/10.1093/ndt/12.3.564Test
http://academic.oup.com/ndt/article-pdf/12/3/564/9907030/120564.pdfTest